MI-LINEAGE-LOGISTICS
2.11.2021 08:02:13 CET | Business Wire | Pressemeddelelse
Lineage Logistics, LLC (”Lineage” eller ”selskabet”), en førende global udbyder af temperaturstyret industriel REIT og logistikløsninger, meddelte i dag, at de har afsluttet opkøbet af køleopbevaringsafdelingen i Claus Sørensen Gruppen, en anerkendt operatør inden for køleopbevaring i Danmark.
Købet blev først annonceret den 15. juni 2021.
Udvidelsen i Danmark er en afgørende del af Lineages vækstplaner i Norden. Opkøbet giver Lineages globale rækkevidde en vigtig forbindelse til Danmark, som er ved at udvikle sig til et førende europæisk midtpunkt inden for den globale køleopbevaringsforsyningskæde, med luftfragt og søfartsinfrastruktur i verdensklasse.
Virksomhedens nuværende tilstedeværelse i Danmark forstærkes igennem Lineages opkøb af Claus Sørensen og tilføjer betydelige volumener på strategiske lokationer nær danske havne og centre for fødevareproduktion.
”Claus Sørensens relationer og tilgang til forretning vil sætte skub i vores vækstplaner i Norden”, siger Harld Peters, Senior Vice President for Europa hos Lineage. ”Vi ser frem til at arbejde sammen med dem for at betjene vores kunder i hele Europa”.
Claus Sørensen, som har hovedkvarter i Esbjerg, har en kapacitet på næsten en million kubikmeter og 200.000 pallepositioner fordelt på ni lagre og mere end 250 teammedlemmer. Med opkøbet og færdiggørelsen af igangværende byggeri i regionen, vil Lineages samlede fodaftryk i Danmark omfatte 17 lokationer og næsten 300.000 pallepositioner.
Claus Sørensen leverer køleopbevaring til kød og fjerkræ, brød, is, færdigretter, frugt og grønt og mejeriprodukter. Ud over opbevaring leverer virksomheden blæsefrysning, kvalitetskontrol, ordresammensætning og pakning, isproduktion, told og distribution til detailhandel og catering. Claus Sørensen kan fryse 1.800 tons produkter om dagen. Claus Sørensen er som et vigtigt led i den danske fødevare- og drikkevareforsyningskæde gået sammen med sine kunder for at forbedre deres forsyningskædeoperationer, opnå maksimal energiudnyttelse og beskytte miljøet.
”Lineage er stærkt engagerede i både innovation og service, hvilket passer perfekt til vores mangeårige forpligtelse til at være vores kunders foretrukne partner”, siger Jesper Toft Mathiasen, CEO hos Claus Sørensen. ”Vi glæder os til at blive en del af en virksomhed, der deler vores værdier, og til at slå os sammen med Lineages team i regionen for at transformere vores kunders forsyningskæde og hjælpe dem med at få deres forretninger til at vokse”.
Lineage Logistics kom ind på det nordiske marked i 2020. Siden da har virksomheden opkøbt Lundsøe Køl & Frys A/S med kølelagerfaciliteter i Nordjylland og Aarhus, Super Frost Sjælland ApS og Coldstar ApS, udover opkøbet af Claus Sørensen.
Om Lineage Logistics: Lineage Logistics er en førende udbyder af temperaturstyret industriel REIT og logistikløsninger. Firmaet har et globalt netværk på over 400 strategisk placerede faciliteter med en samlet kapacitet på over 60 millioner kubikmeter, der spænder over 19 lande fra Nordamerika, Europa og Asien-Stillehavsområdet. Lineages ekspertise indenfor brugsklare løsninger, deres uovertrufne netværk af fast ejendom og udvikling af innovativ teknologi er med til at øge distributionseffektiviteten, fremme bæredygtighed, minimere spild i forsyningskæden og, vigtigst af alt, som visionær partner med Feeding America, være med til at brødføde verden. Som en anerkendelse af firmaets initiativer inden for innovation og bæredygtighed opnåede Lineage at blive nr. 17 på CNBC Disruptor 50-listen i 2021, nr. 1 som bedste datavidenskabsvirksomhed og samlet nr. 23 på Fast Companys liste over verdens mest innovative virksomheder i 2019, udover at være med på Fortunes Change The World-liste i 2020. (www.lineagelogistics.com )
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20211102005519/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
